Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346515 · ClinicalTrials.gov registry record · NA
EPIC US Feasibility Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting
A NA study, sponsored by Lumen Biomedical.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00346515: Completed NA study, sponsored by Lumen Biomedical.
NCT00346515 is a NA study that has completed, run by Lumen Biomedical. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00346515, a NA study, has completed, sponsored by Lumen Biomedical.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
Multicenter, prospective, feasibility study designed to demonstrate the performance and safety of the Lumen Biomedical, Inc. FiberNet™ Embolic Protection System as an adjunctive device during carotid artery percutaneous intervention using the Guidant Acculink carotid stent in high surgical risk patients.
Interventions
- DEVICE FiberNet Emboli Protection System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-01 |
| Phase | NA |
What the finished NCT00346515 record still lists
NCT00346515 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which FiberNet Emboli Protection System is the first listed.
NCT00346515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00346515 about?
NCT00346515 is a clinical study titled "EPIC US Feasibility Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting". Multicenter, prospective, feasibility study designed to demonstrate the performance and safety of the Lumen Biomedical, Inc. FiberNet™ Embolic Protection System as an adjunctive device during carotid artery percutaneous intervention using the Guidant Acculink carotid stent in high surgical risk pati...
What is the current status of trial NCT00346515?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2006-06. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00346515?
The interventions under investigation include: FiberNet Emboli Protection System (DEVICE).
Who is sponsoring clinical trial NCT00346515?
This trial is sponsored by Lumen Biomedical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00346515's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia